An Open Letter to Highmark and Independence Blue Cross
Denial of coverage for lecanemab will have devastating consequences for millions of patients and families.
An Open Letter to Highmark and Independence Blue Cross Read More »
Denial of coverage for lecanemab will have devastating consequences for millions of patients and families.
An Open Letter to Highmark and Independence Blue Cross Read More »
Leqembi is the first amyloid beta-directed antibody to be converted from an accelerated approval to a traditional approval for the treatment of Alzheimer’s disease.
FDA Converts Lecanemab to Traditional Approval Read More »
Leqembi significantly reduces progression of memory loss in those with Alzheimer’s disease by about 30%.
ANA administers first lecanemab infusion in PA Read More »
Blood tests for Alzheimer’s biomarkers will be a powerful tool in determining who will benefit from a drug.
Dr. Weisman Quoted in Philadelphia Inquirer Article on Lecanemab Read More »
We hope to serve our community with infusions to help this unmet medical need while continuing to work on the next generation of Alzheimer treatments.
Lecanemab Reduces Cognitive Decline in Alzheimer’s Read More »
Medicare should require safety monitoring and medical expertise in the use of aducanumab.
Dr. Weisman Quoted in NY Times Article on Aducanumab Read More »
While we might not have clear progress, we do have an advance.
Aducanumab: Neither Far Nor Deep Read More »
While various opinions are circulating, and the benefits of this drug are unclear, ANA will continue to monitor the situation and provide updates as information becomes available.